TriSalus enrolls first patient in pressure-enabled drug delivery trial for treating melanoma

TriSalus Life Sciences announced today that it enrolled the first patient in its clinical study of a treatment for metastatic uveal melanoma.

The PERIO-01 clinical study evaluates SD-101, an investigational toll-like receptor 9 (TLR9) agonist in adults with metastatic uveal melanoma through intravascular administration into uveal melanoma liver metastasis lesions in combination with checkpoint inhibitors using the novel pressure-enabled drug delivery (PEDD) approach.

Find out more in the press release.

Categories: Ecosystem News